← Leaderboards
Beatrice S Knudsen
Utah State Higher Education System--University Of Utah
$4,511,116
Attributed
$6,777,434
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $932.6K · FY2008–24$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,777,434 · 5
VA$0 · 1
By mechanism
R01$4,532,637 · 2
P50$1,422,516 · 1
R21$822,281 · 2
I01$0 · 1
Top collaborators
- Hyung L Kim6 shared
- Daniel W Lin6 shared
- Isla Pearl Garraway2 shared
- Anant Madabhushi2 shared
- Nicholas George Nickols2 shared
- Matthew B Rettig2 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsDiagnosisTissuesPathologyDiagnosticCancer DiagnosisBiopsyBaseCessation Of LifeMalignant Neoplasm Of ProstateProstatePrognosticResearch PersonnelSamplingMeasurementProstatectomyRadical ProstatectomyAdverse EffectsClinical TrialsBiological MarkersCancer RiskLaboratoriesPerformanceGuidelines
Grant awards (23)
Pathomics biomarkers for stratification of clear cell kidney cancers$170,988
R21 · FY2024 · CA · contact PI
Predicting Metastatic Progression of High Risk Localized Prostate Cancer$0
I01 · FY2024 · VA
Pathomics biomarkers for stratification of clear cell kidney cancers$215,693
R21 · FY2023 · CA · contact PI
Predicting Metastatic Progression of High Risk Localized Prostate Cancer$0
I01 · FY2023 · VA
Qualifying Multi-Transcript Signatures for Active Surveillance of Prostate Cancer$548,878
R01 · FY2018 · CA
Qualifying Multi-Transcript Signatures for Active Surveillance of Prostate Cancer$95,249
R01 · FY2018 · CA
Qualifying Multi-Transcript Signatures for Active Surveillance of Prostate Cancer$495,841
R01 · FY2017 · CA
Qualifying Multi-Transcript Signatures for Active Surveillance of Prostate Cancer$527,589
R01 · FY2016 · CA
Qualifying Multi-Transcript Signatures for Active Surveillance of Prostate Cancer$500,277
R01 · FY2015 · CA
Qualifying Multi-Transcript Signatures for Active Surveillance of Prostate Cancer$605,552
R01 · FY2014 · CA
Clinical Specimen Management and Characterization Core$272,427
P50 · FY2013 · CA · contact PI
In vivo effects of sulforaphane supplementation on normal human prostate$121,376
R01 · FY2013 · CA
In vivo effects of sulforaphane supplementation on normal human prostate$550,777
R01 · FY2012 · CA
Clinical Specimen Management and Characterization Core$308,785
P50 · FY2012 · CA · contact PI
Clinical Specimen Management and Characterization Core$263,687
P50 · FY2011 · CA · contact PI
In vivo effects of sulforaphane supplementation on normal human prostate$1
R01 · FY2011 · CA
In vivo effects of sulforaphane supplementation on normal human prostate$536,166
R01 · FY2010 · CA
Clinical Specimen Management and Characterization Core$297,940
P50 · FY2010 · CA · contact PI
In vivo effects of sulforaphane supplementation on normal human prostate$95,983
R01 · FY2010 · CA
In vivo effects of sulforaphane supplementation on normal human prostate$454,948
R01 · FY2009 · CA
Clinical Specimen Management and Characterization Core$279,677
P50 · FY2009 · CA · contact PI
Tissue Lysates for Studies of Protein Phosphorylation$198,000
R21 · FY2009 · CA · contact PI
Tissue Lysates for Studies of Protein Phosphorylation$237,600
R21 · FY2008 · CA · contact PI